Emerging therapies in melanoma

Clinical Advances in Hematology and Oncology

Volumn 10, Issue 11, 2012, Pages 742-743

  Wolchok, Jedd D ^a  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

B RAF KINASE; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; DABRAFENIB; INTERLEUKIN 2; IPILIMUMAB; TRAMETINIB; VEMURAFENIB;

COMPUTER ASSISTED TOMOGRAPHY; HUMAN; IMMUNE RESPONSE; IMMUNOTHERAPY; MELANOMA; MULTICENTER STUDY (TOPIC); NOTE; OUTCOME ASSESSMENT; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); QUALITY OF LIFE;

HUMANS; IMMUNOTHERAPY; MELANOMA; QUALITY OF LIFE; SKIN NEOPLASMS; TREATMENT OUTCOME;

EID: 84872695626     PISSN: 15430790     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Note

References (7)

1. Flaherty KT, Infante JR, Daud A, et al. Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations. N Engl J Med. 2012 Sep 29. [Epub ahead of print]
2. Postow MA, Callahan MK, Barker CA, et al. Immunologic correlates of the abscopal effect in a patient with melanoma. N Engl J Med. 2012;366:925-931.
3. Topalian SL, Hodi FS, Brahmer JR, et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med. 2012;366:2443-2454.
4. ClinicalTrials. gov. Study of immunotherapy to treat advanced prostate cancer. http://clinicaltrials.gov/show/NCT00861614. Identifier: NCT00861614.
5. ClinicalTrials. gov. Pilot ipilimumab in stage IV melanoma receiving palliative radiation therapy. http://clinicaltrials.gov/show/NCT01449279. Identifier: NCT01449279.
6. Postow MA, Harding J, Wolchok JD. Targeting immune checkpoints: releasing the restraints on anti-tumor immunity for patients with melanoma. Cancer J. 2012;18:153-159.
7. Postow MA, Callahan MK, Wolchok JD. The antitumor immunity of ipilimumab: (T-cell) memories to last a lifetime? Clin Cancer Res. 2012;18:1821-1823.